Agios CEO Fouse On Building A Sustainable Business Model
Executive Summary
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.
You may also be interested in...
Agios Reports Phase III Success With Oral Drug For Thalassemia
The company hopes to position mitapivat as an oral treatment for patients across the thalassemia spectrum. A Phase III trial in non-transfusion-dependent alpha- or beta-thalassemia was positive.
Agios Recruits Rare Disease Leader Brian Goff As CEO To Execute Commercial Transition
Leadership change comes after CEO Jackie Fouse, who will serve as board chair, oversaw the sale of Agios' cancer portfolio, a reorganization and a shift in therapeutic focus to rare diseases.
Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval
The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.